Sponsor or institution

Clinical trials and research at Beijing Biotech

• 32Clinical trials
• 1Country

Newest trials

All recruiting trials (32)

• Adaptive Dual-Target CAR-NK Therapy for Relapsed or Refractory SCLC

  This trial tests three dual-target CAR-NK cell products to see if they are safe and show early signs of activity in adults with relapsed or refractory small cell lung cancer.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07744256

• Dual-target PSMA/PSCA CAR-NK Therapy in Advanced Prostate Cancer

  This trial tests ETB-DualNK-01, a dual-target CAR-NK cell therapy, in adults with metastatic castration-resistant prostate cancer to see if it is safe and shows early signs of activity.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07641049

• Dual-target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

  This trial tests a ready-to-use CAR-NK cell therapy that targets HER2 and CEACAM5 in adults with unresectable or metastatic biliary tract cancers after standard therapy to see if it can help control the disease.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07641036

• Dual-target CAR-NK Cells for NSCLC That Co-express MSLN and EGFR or HER2

  This Phase 1/2 study tests off-the-shelf CAR-NK cells targeted to two tumor markers in advanced NSCLC to see if they’re safe and show anti-tumor activity.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07641023

• Dual-target CAR-NK cells targeting MSLN + MUC1 or CLDN18.2 + MUC1 in advanced PDAC

  Aimed at people with advanced pancreatic cancer, this trial tests two off-the-shelf CAR-NK cell products to see if they are safe and can slow or shrink tumors.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07627711

• Dual-target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

  This study tests a donor-derived CAR-NK cell therapy that targets CSPG4 or GD2 in adults with unresectable or metastatic melanoma after standard treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07627698

• Dual-target CLDN18.2/HER2 CAR-NK cells for advanced esophageal cancer

  This trial tests a ready-to-use CAR-NK cell therapy that targets CLDN18.2 and HER2 in adults with recurrent or metastatic esophageal adenocarcinoma who have biomarker-positive tumors.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07622940

• EGFR/HER2 dual-target CAR-NK cells for recurrent or metastatic HNSCC

  This trial tests an allogeneic CAR-NK cell therapy that targets EGFR and HER2 in adults with recurrent or metastatic head and neck cancer that express both biomarkers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07617805

• Dual-target CAR-NK Cells for Peritoneal Cancers of the Ovary, Fallopian Tube, or Pseudoperitoneal Disease

  This trial tests a dual-target CAR-NK cell therapy for people with recurrent or hard-to-treat epithelial ovarian, fallopian tube, or primary peritoneal cancer who express two or more specific tumor markers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07617753

• Target-Selected CAR-NK Cells for B2 Thymoma or Thymic Carcinoma

  This study tests whether CAR-NK cells targeting CD30, CD5, or mesothelin can be safely given to adults whose B2 thymoma or thymic carcinoma has come back or not responded to treatment.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07598955

• Dual-Target CAR-NK Cells for Recurrent or Refractory Epithelial Ovarian Cancer

  This trial tests EB-DUALNK, a dual-target CAR-NK cell therapy, in adults with recurrent or refractory epithelial ovarian, fallopian tube, or peritoneal cancer to see if it can safely help the cancer shrink or stay controlled.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07589543

• TROP2-targeted CAR-NK cell therapy for advanced solid tumors

  This study tests EB-NK-301, an off-the-shelf CAR-NK cell therapy, in adults with advanced or metastatic TROP2-expressing solid tumors after standard treatments have failed.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07589530

• Dual-target CAR-NK therapy for advanced colorectal cancer

  This trial tests an off-the-shelf CAR-NK cell treatment that targets two colorectal cancer markers in adults with unresectable or metastatic disease.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07589517

• Dual-target CAR-NK therapy against CLDN18.2 and HER2 for advanced stomach/GEJ cancer

  This trial will test an off-the-shelf, cord-blood-derived CAR-NK cell therapy that targets CLDN18.2 and HER2 in adults with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have progressed after at least two prior treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07551362

• Dual-target CD70 and CAIX CAR-NK therapy for advanced clear cell kidney cancer

  This trial will try an off-the-shelf CAR-NK cell treatment that targets CD70 and CAIX for adults with advanced or metastatic clear cell kidney cancer who have progressed after standard therapies.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07551349

• Dual-target CAR-NK therapy for adults with recurrent or progressive glioblastoma and other high-grade gliomas

  This study will try giving dual-target CAR-NK cells into the surgical cavity to see if they can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07551336

• Adaptive dual-target CAR-T therapy for relapsed or refractory blood cancers

  This trial will test whether matching a patient's cancer markers to one of several dual-target CAR-T therapies can work and be safe for adults whose blood cancer has come back or not responded.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07523555

• Biomarker-guided CAR-T target selection for refractory lupus

  This trial tests whether using a lab-based immune profile to pick CD19- or BCMA-targeted CAR-T can help adults with refractory lupus, including lupus nephritis, who have not responded to standard treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07523542

• Personalized dual-target CAR-T therapy for advanced solid tumors

  This trial will test personalized dual-target CAR-T cells, matched to tumor biomarker patterns, in adults with advanced unresectable or metastatic solid cancers to see if dual targeting improves tumor control and safety.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07523529

• Precision-matched donor CAR-NK cell therapy targeting one or two tumor antigens for advanced solid tumors

  This trial tests banked donor CAR‑NK cell infusions matched to the antigens in an adult's tumor to see if they are safe and can shrink advanced solid tumors.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07510828

• Dual-target mesothelin and FAP CAR-NK therapy for pleural and peritoneal mesothelioma

  This trial will try locoregional dual-target CAR-NK cells that attack mesothelin on tumor cells and FAP in the tumor stroma in adults with unresectable, recurrent, or refractory pleural or peritoneal mesothelioma who test positive for both markers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07510815

• Dual-target CAR-NK therapy for advanced HER2-positive and triple-negative breast cancer

  This trial will test a dual-target CAR-NK cell therapy in adults with advanced HER2-positive or triple-negative breast cancer who have progressed on or cannot receive standard treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07510802

• Dual-target GD2 and B7-H3 CAR-NK therapy for children and young adults with relapsed or refractory neuroblastoma

  This trial tries an off-the-shelf CAR-NK cell treatment that targets GD2 and B7-H3 for children and young adults whose high-risk neuroblastoma has returned or not responded to prior therapy.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07502287

• Dual-target GPC3 and B7-H3 CAR‑NK therapy for advanced liver cancer

  This trial will test an off‑the‑shelf CAR‑NK cell therapy that targets GPC3 and B7‑H3 in adults with advanced hepatocellular carcinoma who have progressed on or cannot take standard treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07500220

• Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma

  This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07492628

• Dual-target CAR-NK therapy for advanced HER2-positive and triple-negative breast cancer

  This test gives a personalized dual-target CAR-NK cell infusion after short-course chemo to see if it is safe and can shrink tumors in adults with advanced HER2-positive or triple-negative breast cancer whose tumors express HER2, MUC1, or ROR1.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07486089

• Dual-target CAR-NK therapy for recurrent ovarian, fallopian tube, or primary peritoneal cancer

  This trial tests whether dual-target CAR‑NK cells can shrink tumors in people with recurrent or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer whose tumors express at least two of MSLN, FRα, or MUC16.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07480954

• Dual-target CAR-NK cell therapy for recurrent glioblastoma and high-grade glioma

  This phase 1 study will test whether injecting dual-target CAR-NK cells into the brain is safe and can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07480941

• Dual-target CAR-NK therapy targeting mesothelin and MUC1 for advanced pancreatic cancer

  This study will test whether two off-the-shelf CAR-NK cell therapies that target mesothelin or MUC1 are safe and can shrink tumors in people with advanced pancreatic cancer whose tumors express those proteins.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07480928

• Adaptive Phase 1/2 testing dual-target CAR‑NK cells for relapsed or refractory small cell lung cancer

  This trial tests off-the-shelf dual-target CAR‑NK cell therapy in adults with relapsed or refractory extensive-stage small cell lung cancer to see if it is safe and can shrink tumors.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07480213

• Off-the-shelf dual-target CAR-NK cell therapy for advanced non-small cell lung cancer targeting MSLN with EGFR or HER2

  This study tests off-the-shelf CAR-NK cells matched to tumors that express two of MSLN, EGFR, or HER2 in people with advanced or metastatic non-small cell lung cancer.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07467863

• Dual-target CAR-NK therapy for advanced colorectal cancer with CEA, GUCY2C, or HER2 markers

  This trial tests an off-the-shelf CAR-NK cell treatment that targets two tumor markers to see if it can shrink tumors in adults with advanced or metastatic colorectal cancer whose tumors express those markers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07462650

Quick answers

How many clinical trials run by Beijing Biotech are recruiting right now?

32, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 28, Phase 1: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →